CÁNCER DE MAMA
![Foto de CÁNCER DE MAMA](/img/grupo.png)
![Foto de Hospital Universitario de Canarias](/img/noimage_org.png)
Hospital Universitario de Canarias
San Cristóbal de La Laguna, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario de Canarias (8)
2023
-
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR
2018
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428